ABSTRACT. MicroRNAs (miRs) are associated with tumor progression in various cancers, such as gastric and hepatic carcinomas, and lung cancer. miR-301a is overexpressed and displays oncogenic activity in cancers. We investigated the biological involvement of miR301a in osteosarcoma (OS). Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze expression levels of miR-301a in 24 OS and matched adjacent non-tumor tissues. A miR-301a mimic was transferred into OS cell lines U-2 OS and MG-63 to upregulate miR-301a. The effects of miR-301a were investigated by examining cell proliferation, migration, and the cell cycle. The miR-301 target was predicted by TargetScan and confirmed by western blotting and qRT-PCR. The expression of miR-301a was significantly higher in OS tissues compared with the matched adjacent non-tumor tissues (0.959 ± 0.39 vs 3.9516 ± 1.18). Upregulated miR-301a significantly increased proliferation at 48 and 72 h compared to the negative control (U-2 OS: 2.11 ± 0.21 vs 2.88 ± 0.24; 2.70 ± 0.26 vs 3.71 ± 0.24; MG-63: 2.19 ± 0.20 vs 3.19 ± 0.22; 3.1 ± 0.25 vs 4.01 ± 0.27) and migration capability (U-2 OS: 100 ± 20.19 vs 150.68 ± 32.83; MG-63: 100 ± 17.20 vs 133.35 ± 26.26), and decreased apoptosis in both U-2 OS (10.87 ± 2.53 vs 4.01 ± 2.23) and MG-63 (15.26 ± 2.15 vs 8.25 ± 3.07). The cell cycle studies revealed that miR-301a caused an increase of the G2 population in U-2 OS (38.6 ± 6.58 vs 47.2 ± 7.27) and . Additional experiments indicated that CDC14A was upregulated by miR-301a (0.63 ± 0.06 vs 0.98 ± 0.06; 1.49 ± 0.25 vs 2.99 ± 0.14). Overexpressed miR-301a may increase CDC14A expression and promote cell proliferation and migration in OS cells. Therefore, miR301a may be useful for osteosarcoma diagnosis and therapy.
INTRODUCTION
Osteosarcoma (OS) is the most frequent primary human sarcoma of the bone and a leading cause of cancer death, mainly in children and adolescents owing to its rapid proliferation (Mirabello et al., 2009; Jiang et al., 2014) . Survival for these patients is poor, even following surgery and/or radiotherapy (Lewis, 2009; Cho et al., 2011) . Therefore, the mechanisms by which effector molecules and signaling pathways affect the formation and development of OS have been extensively studied.
MicroRNAs (miRNAs) are a class of endogenous small non-coding RNAs that regulate various target mRNAs at the level of mRNA degradation or translation (Van Wynsberghe et al., 2011; Ameres and Zamore, 2013; Cipolla, 2014) . They are regulated in several diseases including cancers, where they have been characterized as oncogenes, tumor suppressors, or as components of regulatory pathways that are critical for tumorigenesis (Tang and Fang, 2009; Suzuki et al., 2012) . miRNAs have potential as biomarkers and therapeutic targets for various tissues and cells in a clinical context. To date, miRNAs and their roles in OS development have attracted much attention. Some of them, including miR-93, -124, -137, -150, -202, and -300 are involved in the initiation and progression of OS, and modulate the biological properties of cancer cells (Karbasy et al., 2015; Kawano et al., 2015; Li et al., 2015a; Li et al., 2015b; Lin et al., 2016; Zhang et al., 2015a) .
The authors of a recent study reported that miR-301a is upregulated in pancreatic cancer via negative regulation of SMAD4 (Xia et al., 2015) . Another study demonstrated that miR-301a regulates the function of myelin-reactive T-helper type 17 cells to control autoimmune demyelination (Mycko et al., 2012) . These studies support the role of miR-301a as a candidate for therapeutic targets. However, the role of miR-301a in OS proliferation, invasion, and migration remains unknown.
In this study, we investigated the potential function of miR-301a in OS carcinogenesis and found that upregulation of miR-301a occurred in OS tissues compared with the corresponding adjacent tissues. In addition, an in vitro study revealed that upregulation of miR-301a significantly increased the proliferation and migration capability, and reduced apoptosis in both U-2 OS and MG-63 cell lines. The cell cycle studies revealed that miR301a caused an increase of the G2 population. Additional experiments indicated that CDC14A was upregulated by miR-301a. Overall, the results presented here elucidate the underlying mechanism by which miR-301a promotes OS growth and metastasis.
MATERIAL AND METHODS

Tissue samples
Fresh samples from OS and the corresponding normal adjacent tissue were obtained from 24 patients undergoing surgery for OS at Anhui Provincial Hospital between January 2012 and October 2014. The samples were immediately snap-frozen in liquid nitrogen and stored at -80°C until required for RNA extraction. The study was approved by the hospital ethical committee, and every patient received written informed consent.
Cell culture and transfection
The human OS cell lines U-2 OS and MG-63 were purchased from the Cell Bank of the Institute of Biochemistry and Cell Biology, China Academy of Sciences (Shanghai, China). The cells were maintained in Dulbecco's modiðed Eagle's medium (DMEM) (Gibco, Carlsbad, USA) containing 10% fetal bovine serum (FBS, Gibco, Carlsbad, USA) and cultured at 37°C in humidified air containing 5% CO 2 . For transfection, cells were cultured to 80% confluence and transfected with 100 nM miR-301a mimic and 100 nM negative control (NC) using a ribo FECT™ CP Transfection Kit (RiboBio Company, Guangzhou, China) according to the manufacturer instructions. Further treatment was carried out several hours after transfection.
RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA, including miRNA, was extracted from the cell lines and tissue samples using TRIzol reagent (Invitrogen, USA). RNA was translated into complementary DNA (cDNA) using a reverse transcriptase kit (TaKaRa, Dalian, China). qRT-PCR was perforemdt using SYBR ® Premix Ex Taq TM (TaKaRa). PCR was performed in triplicate and analyzed using the ABI 7500 Fast Real-Time PCR system (Applied Biosystems, Life Technologies, USA). The relative quantification values for each miRNA were calculated by the 2 -∆∆Ct method using U6 as an internal reference. The reverse transcriptase (RT) and PCR primers for miR-301a and U6 were purchased from RiboBio (Guangzhou, China).
Proliferation assay
A CCK-8 assay was used to analyze cell proliferation. U-2 OS and MG-63 cells were transfected with either the miR-301a mimic or an NC. After 24 h of transfection, the cells were seeded into a 96-well plate at 5.0 x 10 3 cells/well and cultured for 24, 48, and 72 h. At each time-point, 10 µL CCK-8 reagent (Dojindo, Japan) was added to each well and the cells were incubated for 2 h at 37°C. Spectrometric absorbance at a wavelength of 450 nm was measured using a microplate reader (Spectra Max M5; MD, USA). Each sample was tested in triplicate and all experiments were performed three times.
Cell cycle analysis
After 48 h transfection, the cell cycle was investigated using 100 mg/mL propidium iodide (PI) solution containing 50 mg/mL RNase (Beyotime, Haimen, China) for staining, and subsequently analyzed using FACScan cytofluorometry equipment (Becton Dickinson, NJ, USA).
Apoptosis analysis
Cells were transfected as above; 48 h after transfection, the cells were harvested and washed with ice-cold phosphate-buffered saline (PBS), then stained using an Annexin V Apoptosis Detection Kit (BD Pharmingen, USA). This was followed by flow cytometry analysis. The test was conducted in triplicate per experiment.
Cell migration analysis
The cell migration experiment was performed using Transwell polycarbonate membrane inserts (Millipore, Schwalbach, Germany) on 24-well plates. The cells (5 x 10 4 ) were plated onto the chamber and vascular endothelial growth factor (VEGF) (50 ng/mL) was added to the cellfree medium in the lower chamber. After incubation for 24 h at 37°C, the inserts were rinsed in PBS, and the cells were fixed to the membranes with 4% paraformaldehyde and stained with Hoechst (10 mg/mL). The migrated cells were counted at high-power field.
Western blotting
Cells were transfected as above and 48 h later the total cell extracts were prepared from the cells using Cell and Tissue Protein Extraction Regent (KangChen Bio-Tech, China). Electrophoresis of the samples was carried out on 10% sodium dodecyl sulfate polyacrylamide gel. The proteins were then transferred to nitrocellulose filter membranes. The membranes were blocked for 1 h in 5% bovine serum albumin (BSA) and incubated with CDC14A or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:1000; Cell Signaling Technology, USA) overnight at 4°C, followed by incubation with the appropriate IRDye 800CW-conjugated secondary antibody (1:5000; LI-COR Biosciences, USA). The infrared fluorescence images were obtained using an Odyssey Infrared Imaging System (LI-COR Biosciences).
Statistical analysis
Data are reported as means ± SD. Graphs were drawn using GraphPad Prism v5.0. Data were analyzed using one-way analysis of variance (ANOVA) followed by a t-test. Differences with P < 0.05 were considered statistically signiðcant.
RESULTS
miR-301a is significantly upregulated in OS tissues
To examine the changes of the miR-301a expression in cases of OS, the expression of miR-301a was examined in 24 OS tissue specimens. As shown in Figure1, the expression level of miR-301a was significantly elevated in the primary tumor tissue of patients compared with the corresponding adjacent normal tissue (0.959 ± 0.39 vs 3.9516 ± 1.18). The results of this analysis suggest a relationship between miR-301a and OS. Based on this expression pattern, we therefore chose U-2 OS and MG-63 cells for the following gain-of-function and loss-offunction studies, respectively. 
miR-301a promotes cell proliferation while inhibiting cell apoptosis in the OS cell lines
To detect the functional roles of miR-301a, we then examined the effect of miR301a on cell proliferation, the cell cycle, and cell apoptosis. The CCK-8 assay showed that transfection of the miR-301a mimic significantly promoted cell proliferation in the U-2 OS at 48 and 72 h compared with the negative control (2.11 ± 0.21 vs 2.88 ± 0.24; 2.70 ± 0.26 vs 3.71 ± 0.24), and MG-63 cell proliferation was also been promoted at 48 and 72 h (2.19 ± 0.20 vs 3.19 ± 0.22; 3.1 ± 0.25 vs 4.01 ± 0.27). (Figure 2A-2B) . Furthermore, to investigate the promotion of cell proliferation, we determined the populations of different cell phases in the cell cycle. We found that overexpression of miR-301a significantly increased the population of G2 phase cells in U-2 OS (38.6 ± 6.58 vs 47.2 ± 7.27; Figure 2C ) and MG-63 (44.01 ±5.28 vs 57.9 ± 4.25; Figure 2D ). Additionally, flow cytometry analysis showed that upregulation of miR-301a in both U-2 OS and MG-63 cells inhibited cell apoptosis compared with the control group (10.87 ± 2.53 vs 4.01 ± 2.23, Figure 2E ; 15.26 ± 2.15 vs 8.25 ± 3.07, Figure 2F ).
miR-301a promotes migration in the OS cell lines
The Transwell assays showed that the migration of both the U-2 OS cells (100 ± 20.19 vs 150.68 ± 32.83; Figure 3A ) and the MG-63 cells (100 ± 17.20 vs 133.35 ± 26.26; Figure  3B ) significantly increased after transfection with the miR-301a mimic.
CDC14A is a target of miR-301a in OS cell lines
To gain further insight into the molecular mechanism by which miR-301a affects OS cells, we searched for genes that are targeted by miR-301a using biological target prediction software (TargetScan); CDC14A attracted our attention. The expression levels of both CDC14A protein (0.63 ± 0.06 vs 0.98 ± 0.06; 1.49 ± 0.25 vs 2.99 ± 0.14; Figure 4A -4B) and CDC14A mRNA (1.17 ± 0.24 vs 3.09 ± 0.73; 1.1 ± 0.14 vs 3.92 ± 0.39; Figure 4C -4D) in the U-2 OS and MG-63 cells were dramatically increased by miR-301a. 
DISCUSSION
Osteosarcoma is an aggressive malignant osteoid that grows from the cancerization of cells of mesenchymal origin, which inhibit osteoblastic differentiation (Tian et al., 2015) . The low rate of survival in patients treated with multi-agent therapy necessitates further research into the mechanism underlying OS carcinogenesis. A large number of miRNAs are located inside or close to fragile chromosomal sites that are frequently lost or amplified in cancers, and the correlation between miRNAs and cancer has become a focus for the diagnosis and therapy of cancer (Calin et al., 2004) . In this study, we found that the expression of miR-301a was significantly higher in OS tissue compared with the matched adjacent non-tumor tissue. This outcome indicates that miR-301a is involved in the pathogenesis of OS. miRNAs can act as oncogenes or tumor suppressors, and are involved in numerous cellular processes, playing roles in tumorigenesis by regulating cell differentiation, cell proliferation, and the cell cycle (Song and Ju, 2010; Rottiers et al., 2011; Sandoval and Esteller, 2012; Schotte et al., 2012) . miR-301a has also been shown to have a cancerous function in several human tumors, such as pancreatic, prostate, colorectal, and breast cancers (Ma et al., 2014; Zhang et al., 2014; Xia et al., 2015; Xie et al., 2015) . Furthermore, miR-301a expression is associated with radiotherapy resistance (Su et al., 2014) . However, the role of miR-301a in OS tumor development and metastasis has only recently been investigated and remains largely unknown. In this study, we found that upregulation of miR-301a significantly increased proliferation in both U-2 OS and MG-63 cells. Moreover, the cell cycle studies revealed that miR-301a caused an increase of the G2 phase population. In addition, overexpression of miR301a markedly reduced apoptosis in both U-2 OS and MG-63 cells. These data suggest that the increased expression of miR-301a contributes to the growth of OS cells, and consequently facilitates the advanced development of OS. We also discovered that the migration capability of U-2 OS and MG-63 cells was enhanced after transfection with the miR-301a mimic. This result indicates that an aberrant increase in the level of miR-301a may promote cell migration in OS cell lines. Thus, we confirmed that miR-301a may be a tumor oncogene in OS.
A single miRNA can coordinate a large number of target genes (Lim et al., 2005) . Several miR-301a targets have been identified in different cells, such as SMAD4, TGF-b1, and AMPK (Xia et al., 2015; Xie et al., 2015; Zhang et al., 2015b) . To investigate the mechanism by which miR-301a influences OS oncogenesis, we used TargetScan to identify possible mRNA targets, and CDC14A attracted our attention. CDC14A can act independently of its function in the cell cycle (Clément et al., 2012) . CDC14A has been identified as a regulator of centrosome duplication, and it has been suggested that it participates in the control of mitotic entry (Mailand et al., 2002) . In addition, CDC14A phosphatase impairs the timing of mitotic entry by affecting cyclin-dependent kinase 1 (CDK1)-cyclin B1 activity (Vázquez-Novelle et al., 2010) . Here, we used qRT-PCR and western blotting analysis to determine whether the expression of CDC14A was upregulated after miR-30a transfection in OS cell lines. We confirmed that CDC14A is one of the target genes of miR-301a.
In conclusion, our data suggest that miR-301a might be useful as a biomarker of potentially malignant tumors. We also demonstrated that miR-301a promotes proliferation and migration, and reduces apoptosis by targeting CDC14A in osteosarcoma. Thus, miR-301a may be a useful tool in OS diagnosis and therapy.
